帕立骨化醇治疗血液透析患者并发SHPT的效果观察

doi:10.3969/j.issn.1000-8535.2023.04.004

广州医药 ›› 2023, Vol. 54 ›› Issue (4): 25-28.DOI: 10.3969/j.issn.1000-8535.2023.04.004

帕立骨化醇治疗血液透析患者并发SHPT的效果观察

唐丹, 罗敏虹, 朱浪静, 杨铁城

中山大学附属第八医院（深圳福田）肾内科（深圳 518000）

收稿日期:2022-07-27 出版日期:2023-04-20 发布日期:2023-05-18
通讯作者: 杨铁城,E-mail：yangtcpro@163.com
基金资助:
广东省医学科学技术研究基金-面上项目（A2020349）; 广东省中医药局科研课题-面上项目（20211087）

A clinical observational study of hemodialysis patients with SHPT treated with paricalcitol

TANG Dan, LUO Minhong, ZHU Langjing, YANG Tiecheng

Department of Nephrology,the Eighth Affiliated Hospital of Sun Yat-sen University,Shenzhen 518000,China

Received:2022-07-27 Online:2023-04-20 Published:2023-05-18

摘要/Abstract

摘要： 目的观察帕立骨化醇治疗维持性血液透析并发继发性甲状旁腺功能亢进（SHPT）患者6个月的疗效。方法选取40例血液透析合并 SHPT的患者,分成观察组和对照组,分别使用帕立骨化醇和骨化三醇治疗6个月,监测治疗前、治疗后血清全段甲状旁腺素（iPTH）、血钙、血磷水平。比较2组患者治疗6个月后iPTH、血钙、血磷变化情况。结果治疗6个月后,观察组iPTH水平较对照组下降,观察组血钙水平较对照组上升幅度小,观察组血磷水平较对照组下降。结论帕立骨化醇治疗6个月能显著降低血透并发SHPT患者的iPTH水平,治疗效果显著,且不会增加高钙、高磷血症风险,药物安全性好。

关键词: 维持性血液透析, iPTH, 血钙, 帕立骨化醇

Abstract: Objective To observe the effectiveness of paricalcitol in the 6-month treatment of maintenance hemodialysis patients with secondary hyperparathyroidism（SHPT）．Methods Forty maintenance hemodialysis patients with SHPT were selected and divided into observation group and control group．They were treated with paricalcitol or calcitriol for 6 months,respectively．Serum levels of intact parathyroid hormone（iPTH）,calcium and phosphorus were monitored before and after treatment．The changes of iPTH,calcium and phosphorus were compared between the two groups after 6 months of treatment．Results After 6 months of treatment,the level of iPTH in the observation group decreased significantly compared with the control group,the level of calcium in the observation group increased slightly compared with the control group,and the level of phosphorus in the observation group decreased significantly compared with the control group．Conclusions This observational study shows that paricalcitol can significantly reduce the iPTH level in hemodialysis patients with SHPT after treatment for 6 months,without increasing the risk of hypercalcemia and hyperphosphatemia.

Key words: maintenance hemodialysis, iPTH, serum calcium, parietalcalcitol

唐丹, 罗敏虹, 朱浪静, 杨铁城. 帕立骨化醇治疗血液透析患者并发SHPT的效果观察[J]. 广州医药, 2023, 54(4): 25-28.

TANG Dan, LUO Minhong, ZHU Langjing, YANG Tiecheng. A clinical observational study of hemodialysis patients with SHPT treated with paricalcitol[J]. Guangzhou Medical Journal, 2023, 54(4): 25-28.

参考文献

[1] 毛建萍,张倩,陈靖.慢性肾脏病患者甲状旁腺病变发生机制的研究新进展[J].中华肾脏病杂志,2019,35(8):630-634.
[2] 贺西南,石宏斌.慢性肾脏病继发性甲状旁腺功能亢进的研究进展[J].中国中西医结合肾病杂志,2019,20(5):456-459.
[3] 周加军,张凌.活性维生素 D 及其类似物在 CKD-MBD 中的应用[J].中国血液净化,2018,17(6):370-373.
[4] 国家肾脏疾病临床医学研究中心.中国慢性肾脏病矿物质和骨异常诊治指南概要[J].肾脏病与透析肾移植杂志,2019,28(1):52-57.
[5] Kidney Disease:Improving Global Outcomes(KDIGO)CKD-MBD Update Work Group.KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis,Evaluation,Prevention,and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder(CKD-MBD)[J].Kidney Int Suppl(2011),2017,7(1):1-59.
[6] 程亚芬,孙丹妮,许辉,等.帕立骨化醇治疗维持性血液透析患者继发性甲状旁腺功能亢进的疗效观察[J].国际泌尿系统杂志,2020,40(3):402-406.
[7] 王琦,常靓,李悦,等.帕立骨化醇在维持性血液透析患者中的应用效果分析[J].现代生物医学进展,2018,18(18):3459-3462,3596.
[8] 李京,李霞,王怡.帕立骨化醇治疗血液透析患者伴继发性甲状旁腺功能亢进的疗效观察[J].中国血液净化,2019,18(6):386-389.
[9] 王泰娜,徐斌,刘志红,等.帕立骨化醇治疗血液透析患者伴继发性甲状旁腺功能亢进[J].
肾脏病与透析肾移植杂志,2015,24(1):1-5.
[10] 田滨瑶,徐天华,姚丽.继发性甲状旁腺功能亢进的治疗与进展[J].内科理论与实践,2018,13(4):250-254.
[11] 张雪琴,陆晨.帕立骨化醇与骨化三醇治疗继发性甲状旁腺功能亢进症进展[J].临床肾脏病杂志,2017,17(12):761-764.
[12] OLAIZOLA I,CAORSI H,FAJARDO L,et al.Effectiveness and safety of a 6-month treatment with paricalcitol in patients on hemodialysis with secondary hyperparathyroidism[J].J Bras Nefrol,2016,38(3):302-312.
[13] CHEN X,ZHAO F,PAN W J,et al.Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits[J].World J Clin Cases,2021,9(33):10172-10179.
[14] 魏培丹,贾辰,陈效,等.帕立骨化醇不同起始剂量治疗继发性甲状旁腺功能亢进的效果[J].中国当代医药,2021,28(4):70-72.

帕立骨化醇治疗血液透析患者并发SHPT的效果观察

A clinical observational study of hemodialysis patients with SHPT treated with paricalcitol

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

本文评价

[1]	朱颖辉, 李国刚. 维持性血液透析合并糖尿病患者透析前体液分布特点分析[J]. 广州医药, 2023, 54(4): 96-99.
[2]	何同林, 何兰, 刘俊, 刘俊华, 阮宪东, 朱艳红. 高通量透析模式对改善维持性血液透析患者β2微球蛋白清除率及高血压的影响[J]. 广州医药, 2021, 52(5): 35-39.
[3]	耿梦雅, 苏思敏, 李倩, 张俊娥. 维持性血液透析患者症状负担及其影响因素的分析[J]. 广州医药, 2021, 52(5): 57-63.
[4]	杨杰凤, 成世立. 低分子量肝素在维持性血液透析治疗的疗效及安全性[J]. 广州医药, 2015, 46(2): 79-80.